|
This study summarizes the available data from randomized controlled trials that aim to evaluate the efficacy of newly approved L-glutamine and crizanlizumab on vaso-occlusive episodes in Sickle cell disease patients. Photo by Freedigitalphotos
|
By
Laila Ahmed Ayoub, Abdulaziz Abdulrahman A Bedaiwi, Turki Saleh S Alanazi, Nawaf Saeed A. Almalki, Raghad Shiraz M. Alharthi, Rana Eidhah M. Almalki, Eilaf Khaled A. Alsirhani, Khalid Khalaf M. Alanazi, Rakan Mohammed A. Bedaiwi, Hanan Rizqallah A. Alharbi, Manal Mohammed E Alhawiti, Mohammed Abdullah M Albalawi, Jumanah Faisal I Algoufi, Waleed Khaled Alshehri, Abdulwahab Mousa R Albalawi, Rahaf Ahmed A Alharthy, Ibrahim Mahmoud Ajwah, Waseem Babur Rehmatullah
|